LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced its March 31, 2009 financial results as well as its plans to conduct additional pre-clinical studies to confirm its vaccine adjuvant, BioVant™, can increase the efficacy of flu vaccines, including a potential new H1N1 (swine flu) vaccine. Previously presented BioSante data from three BioVant-adjuvanted flu vaccine pre-clinical studies using the M1 protein, H1N1 (similar to today’s swine flu), H3N1 and H5N1 antigens showed that BioVant effectively delivered flu vaccines and concurrently, enhanced the body’s natural immune responses to flu virus antigens, including the potentially pandemic swine flu.
